2018年12月10日 · IMX-109 is a nanoformulation of curcumin, a substance with significant preclinical evidence of activity in inflammation-driven and age-related diseases, whose clinical use...

IMX-101是美国霍斯顿陆军弹药厂研制的一种低成本DNAN基不敏感炸药，2010年替代梯恩梯装填于1 200枚M795式155 mm榴弹中，2011年大规模生产并装备于陆军和海军陆战队 [31]。

IMX-101 is a high-performance insensitive high explosive composite mixture developed by BAE Systems and the United States Army to replace TNT in artillery shells. [1][2][3][4] IMX stands for "Insensitive Munitions eXplosives", which refers to the purpose of IMX-101: to provide explosive force equivalent to TNT without its sensitivity to shocks ...

2023年12月24日 · Its products portfolio includes Imx-109, a small-molecule agent used for the treatment of solid tumors; Imx-110, a nanoparticle delivery vehicle coloaded with small doses of cytotoxin and cytotoxic agents such as doxorubicin, paclitaxel, carboplatin, PD1 inhibitors, T Cell therapies for triple-negative breast cancer, ovarian cancer, colon ...

2022年4月25日 · IMX-101 and IMX-104 are novel insensitive melt-pour explosives developed and produced by BAE Systems at the Holston Army Ammunition Plant (HSAAP). The U.S. Army has selected these two explosives as common low-cost replacements for legacy explosives TNT and Composition-B used in indirect fire weapons such as artillery and mortar munition systems.

一、安裝各類所得憑單資料電子申報系統(IMX) ( 一) 財政部電子申報繳稅服務網(https://www.tax.nat.gov.tw),首頁下選擇「非個人」--> 「各類所得( 含信託)、非扣繳、境外資金匯回」

2017年1月1日 · A DSIAC energetics subject matter expert (SME) provided a short description of the rationale for the Department of Defense transition from cast-cure PBXN to the maturing technology of a melt-cast IMX/ALIMX based explosive fill, which improves fill efficiency while maintaining the required insensitive munitions and detonation performance ...

IMAGEBAM is a free service with more than 15 years of history, empowering people to upload, share and enjoy images online. Hosting millions of files requires massive ...

2022年1月19日 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation...

IMX-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models -- with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin or curcumin alone, and a wholesale shift in the tumor-immune system microenvironment post administration.